Journal Article
. 2012 Dec;14(1).
doi: 10.1016/S1470-2045(12)70525-9.

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

John R Mackey 1 Miguel Martin  Tadeusz Pienkowski  Janusz Rolski  Jean-Paul Guastalla  Amer Sami  John Glaspy  Eva Juhos  Andrew Wardley  Tommy Fornander  John Hainsworth  Robert Coleman  Manuel R Modiano  Jeferson Vinholes  Tamas Pinter  Alvaro Rodríguez-Lescure  Bruce Colwell  Pierre Whitlock  Louise Provencher  Kara Laing  David Walde  Chris Price  Judith C Hugh  Barrett H Childs  Kimberly Bassi  Mary-Ann Lindsay  Véronique Wilson  Matthieu Rupin  Vincent Houé  Charles Vogel  TRIO/BCIRG 001 investigators  
Affiliations
  • PMID: 23246022
  •     81 citations

Abstract

Background: We compared standard adjuvant anthracycline chemotherapy with anthracycline-taxane combination chemotherapy in women with operable node-positive breast cancer. Here we report the final, 10-year follow-up analysis of disease-free survival, overall survival, and long-term safety.

Methods: BCIRG 001 was an open label, phase 3, multicentre trial in which 1491 patients aged 18-70 years with node-positive, early breast cancer and a Karnofsky score of 80% or more were randomly assigned to adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) or fluorouracil, doxorubicin, and cyclophosphamide (FAC) every 3 weeks for six cycles. Randomisation was stratified according to institution and number of involved axillary lymph nodes per patient (one to three vs four or more). Disease-free survival was the primary endpoint and was defined as the interval between randomisation and breast cancer relapse, second primary cancer, or death, whichever occurred first. Efficacy analyses were based on the intention-to-treat principle. BCIRG 001 is registered with ClinicalTrials.gov, number NCT00688740.

Findings: Enrolement took place between June 11, 1997 and June 3, 1999; 745 patients were assigned to receive TAC and 746 patients were assigned to receive FAC. After a median follow-up of 124 months (IQR 90-126), disease-free survival was 62% (95% CI 58-65) for patients in the TAC group and 55% (51-59) for patients in the FAC group (hazard ratio [HR] 0·80, 95% CI 0·68-0·93; log-rank p=0·0043). 10-year overall survival was 76% (95% CI 72-79) for patients in the TAC group and 69% (65-72) for patients in the FAC group (HR 0·74, 0·61-0·90; log-rank p=0·0020). TAC improved disease-free survival relative to FAC irrespective of nodal, hormone receptor, and HER2 status, although not all differences were significant in these subgroup analyses. Grade 3-4 heart failure occurred in 26 (3%) patients in the TAC group and 17 (2%) patients in the FAC group, and caused death in two patients in the TAC group and four patients in the FAC group. A substantial decrease in left ventricular ejection fraction (defined as a relative decrease from baseline of 20% or more) was seen in 58 (17%) patients who received TAC and 41 (15%) patients who received FAC. Six patients who received TAC developed leukaemia or myelodysplasia, as did three patients who received FAC.

Interpretation: Our results provide evidence that the initial therapeutic outcomes seen at the 5-year follow-up with a docetaxel-containing adjuvant regimen are maintained at 10 years. However, a substantial percentage of patients had a decrease in left ventricular ejection fraction, probably caused by anthracycline therapy, which warrants further investigation.

Funding: Sanofi.

High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.
Tyler J W Robinson, Melody Pai, +6 authors, Eldad Zacksenhaus.
Cell Cycle, 2013 Aug 27; 12(18). PMID: 23974104    Free PMC article.
DNA crosslinking damage and cancer - a tale of friend and foe.
Yaling Huang, Lei Li.
Transl Cancer Res, 2013 Sep 03; 2(3). PMID: 23998004    Free PMC article.
Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis.
Bella Pajares, Marina Pollán, +16 authors, Emilio Alba.
Breast Cancer Res, 2013 Nov 07; 15(6). PMID: 24192331    Free PMC article.
Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.
Michel G Khouri, Whitney E Hornsby, +9 authors, Lee W Jones.
Breast Cancer Res Treat, 2014 Jan 07; 143(3). PMID: 24390149    Free PMC article.
Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer.
Qi Lin, Yang Liu, +4 authors, Hao Chen.
Mol Clin Oncol, 2014 Mar 22; 1(5). PMID: 24649257    Free PMC article.
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.
Sara A Hurvitz, Linda D Bosserman, +6 authors, Dennis J Slamon.
Springerplus, 2014 May 27; 3. PMID: 24860718    Free PMC article.
Past, present, and future challenges in breast cancer treatment.
George W Sledge, Eleftherios P Mamounas, +3 authors, Antonio C Wolff.
J Clin Oncol, 2014 Jun 04; 32(19). PMID: 24888802    Free PMC article.
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Maria Y Ho, John R Mackey.
Cancer Manag Res, 2014 Jun 07; 6. PMID: 24904223    Free PMC article.
Review.
Outcome of Breast Cancer Patients Treated outside of Clinical Trials.
Nagi S El Saghir, Hussein A Assi, +5 authors, Toufic A Eid.
J Cancer, 2014 Jun 25; 5(6). PMID: 24959302    Free PMC article.
Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial.
Lee W Jones, Pamela S Douglas, +5 authors, Christopher M O'Connor.
J Clin Oncol, 2014 Jul 09; 32(23). PMID: 25002717    Free PMC article.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Nicole M Davis, Melissa Sokolosky, +23 authors, James A McCubrey.
Oncotarget, 2014 Jul 23; 5(13). PMID: 25051360    Free PMC article.
Highly Cited. Review.
Rat injury model of docetaxel extravasation.
Jing-Jing Zhu, Jian-Fei Fu, +3 authors, Jian-Hua Yu.
Biomed Rep, 2014 Jul 24; 2(5). PMID: 25054005    Free PMC article.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Review.
Update on adjuvant chemotherapy for early breast cancer.
Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard.
Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961    Free PMC article.
Review.
Anti-hepatoma activity of a novel compound glaucocalyxin H in vivo and in vitro.
Guangfan Hai, Chong Zhang, +7 authors, Yu Song.
AAPS PharmSciTech, 2014 Nov 07; 16(3). PMID: 25374342    Free PMC article.
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy.
Elizabeth Miller, Hee Jin Lee, +3 authors, Bora Lim.
F1000Res, 2014 Nov 18; 3. PMID: 25400908    Free PMC article.
Review.
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer.
Changhoon Yoo, Sung-Bae Kim, +9 authors, Woo Kun Kim.
Cancer Res Treat, 2015 Feb 05; 47(3). PMID: 25648092    Free PMC article.
A Brief History of Breast Cancer: Part III - Tumour biology lays the foundation for medical oncology.
Ritu Lakhtakia, Ikram Burney.
Sultan Qaboos Univ Med J, 2015 Feb 17; 15(1). PMID: 25685382    Free PMC article.
Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.
Norikazu Masuda, Yutaka Tokuda, +3 authors, Kazuo Tamura.
Support Care Cancer, 2015 Mar 04; 23(10). PMID: 25733000    Free PMC article.
Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.
Brittany Haynes, Nadia Saadat, Brian Myung, Malathy P V Shekhar.
Mutat Res Rev Mutat Res, 2015 Mar 22; 763. PMID: 25795124    Free PMC article.
Review.
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Wei Zhang, Zhiwei Jiang, +2 authors, Jielai Xia.
Med Oncol, 2015 Mar 31; 32(5). PMID: 25820754
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Review.
Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Meyha N Swaroop, Chantal M Ferguson, +8 authors, Alphonse G Taghian.
Breast Cancer Res Treat, 2015 May 06; 151(2). PMID: 25940996    Free PMC article.
Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials.
Rodrigo Fresco, Gonzalo Spera, +2 authors, John R Mackey.
Oncologist, 2015 May 31; 20(7). PMID: 26025934    Free PMC article.
β3-tubulin is a good predictor of sensitivity to taxane-based neoadjuvant chemotherapy in primary breast cancer.
Youqun Xiang, Yinlong Yang, +4 authors, Yifei Pan.
Clin Exp Med, 2015 Jun 20; 16(3). PMID: 26088183
Treatment Outcome of Breast Cancer with Pathologically Proven Synchronous Ipsilateral Supraclavicular Lymph Node Metastases.
Jinhong Jung, Su Ssan Kim, +5 authors, Eun Kyung Choi.
J Breast Cancer, 2015 Jul 15; 18(2). PMID: 26155293    Free PMC article.
Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms.
Ching-Ying Kuo, Wen-Cheng Chou, +5 authors, Hui-Chun Wang.
Oncotarget, 2015 Jul 26; 6(28). PMID: 26208482    Free PMC article.
Current knowledge and future research directions in treatment-related second primary malignancies.
Lindsay M Morton, Anthony J Swerdlow, +4 authors, Flora E van Leeuwen.
EJC Suppl, 2015 Jul 29; 12(1). PMID: 26217162    Free PMC article.
Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.
Michel G Khouri, Michael R Klein, Eric J Velazquez, Lee W Jones.
Future Cardiol, 2015 Aug 04; 11(4). PMID: 26235924    Free PMC article.
Review.
Progress in adjuvant chemotherapy for breast cancer: an overview.
Jesus Anampa, Della Makower, Joseph A Sparano.
BMC Med, 2015 Aug 19; 13. PMID: 26278220    Free PMC article.
Highly Cited. Review.
Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Takeo Fujii, Fanny Le Du, +6 authors, Naoto T Ueno.
JAMA Oncol, 2015 Sep 25; 1(9). PMID: 26402167    Free PMC article.
Systematic Review.
A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Lina Wu, Lu Yao, +8 authors, Yuntao Xie.
Oncotarget, 2015 Nov 18; 7(4). PMID: 26573232    Free PMC article.
Protective role of Osthole on myocardial cell apoptosis induced by doxorubicin in rats.
Hongdang Xu, Yu Han, +2 authors, Chuanyu Gao.
Int J Clin Exp Pathol, 2015 Dec 01; 8(9). PMID: 26617794    Free PMC article.
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
W Janni, N Harbeck, +9 authors, M Kiechle.
Br J Cancer, 2016 Apr 01; 114(8). PMID: 27031854    Free PMC article.
Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.
Rui-Min Ma, Chuan-Zhi Chen, +3 authors, Gui-Long Guo.
Medicine (Baltimore), 2016 Apr 05; 95(13). PMID: 27043697    Free PMC article.
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Cun Wang, Haojie Jin, +10 authors, Wenxin Qin.
Theranostics, 2016 Jun 10; 6(8). PMID: 27279912    Free PMC article.
Highly Cited.
Real-world adjuvant TAC or FEC-D for HER2-negative node-positive breast cancer in women less than 50 years of age.
S Lupichuk, D Tilley, X Kostaras, A A Joy.
Curr Oncol, 2016 Jun 23; 23(3). PMID: 27330344    Free PMC article.
Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
Anastasia S Proskurina, Tatiana S Gvozdeva, +17 authors, Sergey S Bogachev.
BMC Cancer, 2016 Aug 20; 16. PMID: 27538465    Free PMC article.
Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
G Houvenaeghel, R Sabatier, +11 authors, E Lambaudie.
Br J Cancer, 2016 Oct 26; 115(9). PMID: 27685443    Free PMC article.
Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418).
Yeon-Joo Kim, Won Park, +22 authors, Jihye Cha.
Cancer Res Treat, 2017 Jan 06; 49(4). PMID: 28052654    Free PMC article.
Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.
Hari K Narayan, Brian Finkelman, +5 authors, Bonnie Ky.
Circulation, 2017 Jan 21; 135(15). PMID: 28104715    Free PMC article.
Cardiac mechanics and dysfunction with anthracyclines in the community: results from the PREDICT study.
Hari K Narayan, Wei Wei, +5 authors, Bonnie Ky.
Open Heart, 2017 Jan 27; 4(1). PMID: 28123764    Free PMC article.
Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
Qiu-Wen Tan, Ting Luo, +5 authors, Qing Lv.
Chin J Cancer, 2017 Mar 09; 36(1). PMID: 28270181    Free PMC article.
Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report.
Murat Özgür Kılıç, Metin Yalaza, Celal İsmail Bilgiç, Cenap Dener.
J Breast Health, 2015 Jan 01; 11(2). PMID: 28331700    Free PMC article.
Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer.
Janine T Hidding, Carien H G Beurskens, +3 authors, Hanneke W M van Laarhoven.
Support Care Cancer, 2017 Nov 12; 26(5). PMID: 29127528    Free PMC article.
The paradox of the first cycle of chemotherapy-transient improvement of contractility and diastolic function after the first cycle of anthracycline-based chemotherapy: a prospective clinical trial.
Paweł Stachowiak, Andrzej Wojtarowicz, +4 authors, Zdzisława Kornacewicz-Jach.
Oncotarget, 2017 Dec 10; 8(56). PMID: 29221219    Free PMC article.
Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells.
Zunyue Zhang, Guohong Lin, +7 authors, Xiang-Ping Yang.
Oncogene, 2018 Mar 22; 37(25). PMID: 29559745    Free PMC article.
Radiation induced secondary malignancies: a review article.
Chinna Babu Dracham, Abhash Shankar, Renu Madan.
Radiat Oncol J, 2018 Jul 10; 36(2). PMID: 29983028    Free PMC article.
Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies.
Binghe Xu, Zhimin Shao, +7 authors, Shu Wang.
Chin J Cancer Res, 2018 Jul 27; 30(3). PMID: 30046227    Free PMC article.
Cardio-oncology: protecting the heart from curative breast cancer treatment.
Jenica N Upshaw.
Gland Surg, 2018 Sep 04; 7(4). PMID: 30175052    Free PMC article.
Review.
Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Guoding Huang, Jianfeng Zhai, Xinting Huang, Dongdan Zheng.
Medicine (Baltimore), 2018 Sep 22; 97(38). PMID: 30235730    Free PMC article.
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
Florence R Wilson, Megan E Coombes, +7 authors, Chris Cameron.
Syst Rev, 2018 Nov 16; 7(1). PMID: 30428932    Free PMC article.
Systematic Review.
Taxanes for adjuvant treatment of early breast cancer.
Melina L Willson, Lucinda Burke, +3 authors, Nicholas Wilcken.
Cochrane Database Syst Rev, 2019 Sep 03; 9. PMID: 31476253    Free PMC article.
Systematic Review.
The Effects of Doxorubicin-based Chemotherapy and Omega-3 Supplementation on Mouse Brain Lipids.
Djawed Bennouna, Melissa Solano, +3 authors, Rachel E Kopec.
Metabolites, 2019 Oct 02; 9(10). PMID: 31569490    Free PMC article.
Tumor Drug Distribution after Local Drug Delivery by Hyperthermia, In Vivo.
Helena C Besse, Angelique D Barten-van Rijbroek, +3 authors, Roel Deckers.
Cancers (Basel), 2019 Oct 12; 11(10). PMID: 31600958    Free PMC article.
Chemotherapy in conjunction with traditional Chinese medicine for survival of patients with early female breast cancer: protocol for a non-randomized, single center prospective cohort study.
Chien-Ting Liu, Yen-Hao Chen, +2 authors, Ming-Yen Tsai.
Trials, 2019 Dec 19; 20(1). PMID: 31847861    Free PMC article.
Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease : An individual patient data analysis of three clinical trials.
Omar Abdel-Rahman.
Strahlenther Onkol, 2018 Aug 03; 195(4). PMID: 30069737
Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors.
Judy N Jacobse, Frances K Duane, +10 authors, Carolyn W Taylor.
Int J Radiat Oncol Biol Phys, 2018 Nov 06; 103(3). PMID: 30385276    Free PMC article.
Comment to Impact of postmastectomy radiotherapy on the outcomes of breast cancer patients with T1-2 N1 disease; an individual patient data analysis of three clinical trials.
Christiane Matuschek, David Krug, Rainer J Klement, René Baumann.
Strahlenther Onkol, 2019 Jan 06; 195(4). PMID: 30610353
Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells.
Maria Pereira-Oliveira, Ana Reis-Mendes, +3 authors, Vera Marisa Costa.
Biomolecules, 2019 Jan 13; 9(1). PMID: 30634681    Free PMC article.
Early Detection and Monitoring of Cancer Chemotherapy-Related Left Ventricular Dysfunction by Imaging Methods.
Mario Luiz Ribeiro, Antonio José Lagoeiro Jorge, Marcelo Souto Nacif, Wolney de Andrade Martins.
Arq Bras Cardiol, 2019 Mar 28; 112(3). PMID: 30916206    Free PMC article.
Review.
Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Jenica N Upshaw, Robin Ruthazer, +8 authors, David M Kent.
Clin Breast Cancer, 2019 Jun 09; 19(4). PMID: 31175052    Free PMC article.
Heart failure after treatment for breast cancer.
Naomi B Boekel, Fran K Duane, +11 authors, Flora E van Leeuwen.
Eur J Heart Fail, 2019 Nov 14; 22(2). PMID: 31721395    Free PMC article.
The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy.
Erina Hilaj, Alketa Ymeri, Kleva P Shpati.
Cureus, 2020 Apr 08; 12(2). PMID: 32257663    Free PMC article.
Detailed phenotyping reveals distinct trajectories of cardiovascular function and symptoms with exposure to modern breast cancer therapy.
Biniyam G Demissei, Brian S Finkelman, +17 authors, Bonnie Ky.
Cancer, 2019 May 02; 125(16). PMID: 31042319    Free PMC article.
Genetic Factors Involved in Cardiomyopathies and in Cancer.
María Sabater-Molina, Marina Navarro-Peñalver, +3 authors, Juan R Gimeno.
J Clin Med, 2020 Jun 06; 9(6). PMID: 32498335    Free PMC article.
Review.
The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients.
Wanwan Qi, Xiaoyi Wang, +3 authors, Qiao Cheng.
Sci Rep, 2020 Aug 09; 10(1). PMID: 32764734    Free PMC article.
Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer.
Blanca Prieto-Callejero, Francisco Rivera, +4 authors, Carlos Ruiz-Frutos.
Medicine (Baltimore), 2020 Sep 03; 99(33). PMID: 32872042    Free PMC article.
Secondary lymphoma develops in the setting of heart failure when treating breast cancer: A case report.
Sen Han, Tao An, +2 authors, Jun Zhu.
World J Clin Cases, 2019 Aug 01; 7(12). PMID: 31363478    Free PMC article.
Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient - a case report.
Rajkumar Ramaswamy, Nisarg Joshi, Mujtaba A Khan, Seerin Siddhara.
Onco Targets Ther, 2019 Aug 14; 12. PMID: 31406465    Free PMC article.
Effects of Chemotherapy on Serum Lipids in Chinese Postoperative Breast Cancer Patients.
Qi Lu, Xian Wu, +10 authors, Xiaoan Liu.
Cancer Manag Res, 2020 Sep 29; 12. PMID: 32982433    Free PMC article.
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy.
Ye Won Jeon, Seung Taek Lim, +2 authors, Young Jin Suh.
J Breast Cancer, 2020 Nov 07; 23(5). PMID: 33154827    Free PMC article.
Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.
Naomi B Boekel, Judy N Jacobse, +13 authors, Flora E van Leeuwen.
Br J Cancer, 2018 Aug 02; 119(4). PMID: 30065254    Free PMC article.
Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418).
Gyu Sang Yoo, Won Park, +14 authors, Jihye Cha.
Cancer Res Treat, 2018 Nov 06; 51(3). PMID: 30384580    Free PMC article.
Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology.
Panagiotis Ntellas, Nikolaos Spathas, +2 authors, Emmanouil Saloustros.
Oncotarget, 2019 Mar 07; 10(11). PMID: 30838092    Free PMC article.
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells.
Ana Reis-Mendes, Félix Carvalho, +3 authors, Vera Marisa Costa.
Biomolecules, 2019 Mar 14; 9(3). PMID: 30862114    Free PMC article.
N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target.
John R Mackey, Justine Lai, +8 authors, Luc G Berthiaume.
Breast Cancer Res Treat, 2021 Jan 06; 186(1). PMID: 33398478    Free PMC article.
Patient-sharing relationship between Chinese medicine doctors and other physicians: costs and outcomes of breast cancer survivorship care.
Chiu-Mei Yeh, Yiing-Jenq Chou, +2 authors, Nicole Huang.
J Cancer Surviv, 2021 Feb 19;. PMID: 33599958
Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts.
Scott P Levick, David R Soto-Pantoja, +5 authors, Giselle C Meléndez.
Heart Lung Circ, 2018 Sep 13; 28(10). PMID: 30205930    Free PMC article.
Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction.
Biniyam G Demissei, Yong Fan, +8 authors, Bonnie Ky.
Eur Heart J Cardiovasc Imaging, 2020 Nov 19; 22(4). PMID: 33206976    Free PMC article.
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Hyunho Han, Hyung Ho Lee, +8 authors, Young-Deuk Choi.
Prostate Cancer Prostatic Dis, 2021 Apr 28;. PMID: 33903734